Abstract: Bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita are subepidermal autoimmune blistering diseases whose antigenic target is located at the basement membrane zone. Mucous membrane pemphigoid and epidermolysis bullosa acquisita can evolve with cicatricial mucosal involvement, leading to respiratory, ocular and/or digestive sequelae with important morbidity. For each of these dermatoses, a literature review covering all therapeutic options was performed. A flowchart, based on the experience and joint discussion among the authors of this consensus, was constructed to provide treatment orientation for these diseases in Brazil. In summary, in the localized, low-risk or non-severe forms, drugs that have immunomodulatory action such as dapsone, doxycycline among others may be a therapeutic option. Topical treatment with corticosteroids or immunomodulators may also be used. Systemic corticosteroid therapy continues to be the treatment of choice for severe forms, especially those involving ocular, laryngeal-pharyngeal and/or esophageal mucosal involvement, as may occur in mucous membrane pemphigoid and epidermolysis bullosa acquisita. Several immunosuppressants are used as adjuvant alternatives. In severe and recalcitrant cases, intravenous immunoglobulin is an alternative that, while expensive, may be used. Immunobiological drugs such as rituximab are promising drugs in this area. Omalizumab has been used in bullous pemphigoid.
INTRODUCTION
Bullous pemphigoid (BP) accounts for 80% of subepidermal bullous dermatoses. It typically presents as generalized pruritus and tense bullous eruptions and may be associated with a 20% to 40% mortality rate. It primarily affects those aged above 70 years, and its annual incidence is estimated to be at least 13 to 62 new cases per million persons, rising significantly after 60 years old.
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ETIOPATHOGENESIS
In the etiopathogenesis of BP, IgG autoantibodies are produced against antigens of the basement membrane zone (BMZ) -180kDa and 230kDa -collagen XVII, COL17 or BPAg2, and BPAg1, respectively. BP180 is the most relevant antigenic determinant, whereas BP230 appears to be more related to cytoskeletal function and signaling of the dermoepidermal transition. The involvement of mast cells and IgE in the development of BP lesions has recently been described. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The association of malignancies with BP is likely to be related to the incidence of both diseases in the elderly, although some reports have suggested an increase in the frequency of certain cancers, such as those in the digestive tract, lung, and bladder and lymphoproliferative diseases. 20, 21 BP is rarely described in patients with inflammatory or autoimmune diseases. In certain patients, it appears to be triggered by trauma, burns, radiotherapy, or irradiation by ultraviolet rays. BP has also been observed in association with psoriasis and lichen planus. 22 In some patients, systemic medications may lead to the development of BP, including diuretics (furosemide), antibiotics (amoxicillin, ciprofloxacin), potassium iodide, and captopril. The mechanism by which drugs induce BP has not been determined. 23 Of greater interest, BP has been associated with neurological diseases, such as dementia, stroke, multiple sclerosis, epilepsy, and Parkinson disease, but the underlying pathophysiological mechanism is not completely understood. It is possible that the BP antigens BPA 1 and BPA 2 act as autoreactive antigens in the central nervous system and in tegument. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] The HLA class II DQB1*03:01 allele is more prevalent in
Caucasian patients with BP than in the general population and has also been associated with neurological diseases. 37, 38 
CLINICAL CONDITION
The tegumentary manifestations of BP are extremely polymorphic. In the non-blistering phase, the signs and symptoms are usually nonspecific, presenting as isolated pruritus, sometimes in- Localized involvement is uncommon. 31 Oral involvement is observed between 10% and 30% of affected patients. The eyes, nose, pharynx, esophagus, and anogenital regions are rarely affected. 1, 18, [22] [23] [24] 39 by DIF or IIF. [39] [40] [41] In most patients, DIF of non-impaired perilesional skin will demonstrate linear and continuous IgG or C 3 deposition along the BMZ. Furthermore, the salt-split skin (SSS) IIF technique, when treating normal human skin with 1 M NaCl, followed by incubation with the patient's serum, may be useful in distinguishing BP from other subepidermal bullous autoimmune diseases, primarily epidermolysis bullosa acquisita and bullous lupus erythematosus. 40, 41 In BP, immune deposits are found on the epidermal side or on both sides of the cleavage (dermal and epidermal). In 60% to 80% of patients, IgG autoantibodies and, less frequently, IgA and IgE are circulating; these autoantibodies also often bind to the cleavage on the epidermal side. 23 ELISA using recombinant proteins that contain specific regions of BP antigens (eg, BP180 domain NC16A and the C-terminal portion of BP180 or BP230) is useful for the BP diagnosis. The determination of antibodies against BP180 and BP230 may be necessary to confirm the diagnosis; rarely, BP patients have antibodies against desmogleins-ie, pemphigus antigens. 31, 41, 42 Serology may also be used for therapeutic follow-up, especially at the time of treatment discontinuation.
LABORATORY DIAGNOSIS
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TREATMENT
The treatment of BP is based more on clinical experience than on controlled studies. For the extensive form, systemic corticosteroids are the main option, wherein a regimen of oral prednisone of 0.5 to 0.75mg/kg/day is recommended. Large controlled studies have reported the value of potent topical corticosteroids, which also appear to control generalized BP with similar efficacy as systemic corticosteroids and with few side effects. 23, 43 However, the refractory nature of some patients to corticosteroids merits further study.
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Bullous PemPHIGoId t
Eventually, pulse therapy with methylprednisone may be required to control the disease more rapidly. The use of immunosuppressive drugs has been discussed; certain groups advocate their use only as second-line therapy, when monotherapy with corticosteroids fails or if there is any contraindication. The most frequently used agents are azathioprine, mycophenolate mofetil, methotrexate, chlorambucil, and cyclophosphamide. 23, 43 Low doses of cyclophosphamide may have benefits. 46 The combination of nicotinamide and minocycline or tetracycline can be used as a therapeutic alternative.
Dapsone can be administered, especially when there is mucosal involvement, and the value of topical immunomodulators, such as tacrolimus, should be confirmed. 23, 43, 47 In cases of treatment resistance, intravenous immunoglobulin, plasmapheresis, or anti-CD20 immunotherapy (rituximab) may be prescribed. Based on the immunopathogenesis of BP, new compounds are being proposed. [47] [48] [49] Recently, a European consensus was developed for the treatment of BP. 43 The figure 1 that is presented here depicts this consensus with modifications, in addition to the revisions that have been incorporated for the treatment of BP. 
INTRODUCTION
Mucous membrane pemphigoid (MMP), also known as cicatricial pemphigoid, refers to a group of chronic autoimmune diseases that predominantly affect the mucous membranes and, occasionally, skin. 50 It is part of a group of autoimmune dermatoses that present with subepidermal bullous lesions, characterized by the formation of antibodies against structures of the basement membrane zone (BMZ). In MMP, antibodies bind more frequently to BP-180 and laminin 332 (laminin 5). 51 Scarring of lesions on the mucous membranes is common-hence, the term "cicatricial"-which may lead to decreased visual acuity, blindness, supraglottic stenosis with hoarseness, or airway obstruction.
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EPIDEMIOLOGY MMP usually has a late onset, between age 60 and 80 years.
Women appear to be more commonly affected than men, from 1.5 to 2 times more frequently, with no racial or geographic preference. European data show an incidence of approximately 1:1,000,000 people annually. The initial signs and symptoms may be subtle and non-specific, with irreversible and often debilitating consequences.
It is associated with high morbidity and mortality if treatment is not initiated early and aggressively. 54 Fibroblasts also appear to be activated, secondary to the production of cytokines, such as transforming growth factor beta, which is known to induce fibrosis. 
LABORATORY DIAGNOSIS
The diagnosis of MMP is based on the patient's clinical presentation and histopathological characteristics. In these cases, tissue biopsy is extremely important, because the epithelium of MMP patients tends to move easily, rendering the sample inadequate if it is not performed correctly. Selection of the appropriate treatment depends on several factors, including the site that is involved, disease severity, and its progression. 50, 53 Patients can be divided into a low-risk group, with lesions that are restricted to the oral mucosa, and a high-risk group, with ocular, pharyngeal, laryngeal, esophageal, and genital lesions. The treatment for the low-risk group is conservative, prioritizing topical treatment when possible, whereas in the high-risk group, treatment should be aggressive, with early initiation of systemic agents. 53, 58 Due to the absence of large, multicenter, randomized, and controlled clinical trials for this disease group, the treatment strategy is based on expert experience and literature reports.
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Topical treatment
Corticosteroids
Moderate-to high-potency topical corticosteroids are the first-line treatment for low-risk patients who have the disease limited to the oral mucosa with or without cutaneous involvement. A conservative approach is recommended, because there is less risk of scarring in these regions. These agents may also be useful as adjunctive therapy in the most severe cases, constituting important components of the therapeutic arsenal. Corticosteroid gels, ointments, or elixirs can be used 2 to 3 times a day. Gels are applied more easily and better tolerated in the oral cavity. It is important to guide the patient to dry the mucosa before application, rub the medication gently at the site for 30 seconds, and refrain from eating or drinking for 30 minutes. One of the applications should be performed before bedtime, because oral secretions are diminished during sleep. This step may allow the medication to remain longer in the treated area. 60 Alternative methods of administering corticosteroids include trays that are made by dentists to provide medicines under occlusion, for patients with gingival involvement. Trays should be inserted into the dental arch and held for 10 to 20 minutes. 60, 61 If the patient does not respond adequately to topical therapy, injections of intralesional corticosteroids, which have had some success, may be used. The application should be superficial, just below the erosions; if it is deeper, it may increase the risk of mucosal atrophy. Injection of triamcinolone hexacetonide at 5 to 10mg/ml every 2 to 4 weeks is recommended. The total dose that is administered on a per-session basis should not exceed 20mg. 53, 60 Some adverse effects of topical corticosteroids are known, such as mucosal atrophy, oropharyngeal candidiasis, and reactivation of herpes simplex virus. Usually, patients improve in several weeks with the use of topical corticosteroids. As improvement occurs, the patient can gradually decrease the frequency of applications and substitute them for less potent agents, avoiding mucosal atrophy. If treatment discontinuation is not possible due to relapses, the patient should be maintained with the lowest effective topical or systemic maintenance regimen. 
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Oral care
When there is oral cavity involvement, the patient needs to be encouraged to exercise good hygiene. Frequent toothbrushing is indicated using soft-bristled brushes, proper technique, toothpaste that does not contain sodium lauryl sulfate, alcohol-free mouthwash, and flossing to avoid plaque build-up, acceleration of dental caries, and loss of gums and teeth. Topical anesthetics (e.g., lidocaine) may be used to reduce pain by applying them to lesions before meals, brushing, dental procedures, and other occasions. Mild debridement of necrotic mucosal tissue can be performed to prevent infection. Oral cavity trauma using ill-fitting dentures can lead to the formation of new erosions. Thus, regular dental evaluations are imperative in patient care. 60, 67 Extraoral care In addition to pharmacological treatment, other interventions may be useful in the management of patients with extraoral involvement. Early referral to specialists is essential to prevent scars and sequelae in these regions. When there is nasal involvement, lavage with saline, application of emollients, and the use of corticosteroids in spray form may be useful. Esophageal involvement justifies a liquid-pasty diet, measures for preventing gastroesophageal reflux, and dilatation of stenosis. When there is involvement of the anogenital region, corticosteroids, and even topical calcineurin inhibitors, can be indicated. The patient should be guided to consume a laxative diet that is rich in water and fiber intake for digestion and stool excretion. If the disease is not adequately controlled, tetracycline (1 to 2g per day) or doxycycline 100mg/day and nicotinamide (2 to 3g per day) may be used. The adverse effects of tetracycline include gastrointestinal discomfort and phototoxicity. 
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Systemic corticosteroids
Cyclophosphamide
Cyclophosphamide is a rapid and effective therapeutic agent and is reserved for patients with severe, rapidly progressing disease or those who have not responded to other immunosuppressive agents. It can be administered alone (1-2mg/kg/day) or in combination with corticosteroids in high doses (prednisone 1-1.5mg/ kg per day). 53 In some cases, more aggressive treatment with pulse therapy is required at 1g/day or 10-15mg/kg/day, in combination with dexamethasone 100mg on the first day, followed by dexamethasone only on the other 2 days; this cycle may be repeated every 26 days, depending on symptomatology. Regular laboratory monitoring includes a complete differential blood count and urinalysis.
Due to its potential toxicity, cyclophosphamide should be used as a short-term therapy and replaced with an alternative adjuvant after disease control has been achieved. The most common adverse effects are associated with infusion reactions, often related to the rate of administration and hypersensitivity reactions (fever, chills, bronchospasm, pruritus, and hypotension). Rituximab is contraindicated in pregnancy; patients of childbearing age should use effective contraception during its use and up to 12 months afterward.
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Anti-TNF alpha agents
In addition to conventional treatments, anti-TNF alpha agents have been reported to be effective in mucous membrane pemphigoid, perhaps merited by the high serum TNF-alpha levels have a better prognosis and respond well to conservative approaches, whereas high-risk patients (ocular, nasopharyngeal, laryngeal, esophageal, and anogenital mucosa) have a worse prognosis, being poor responders and often experiencing scarring, despite treatment.
In the latter, an early aggressive approach helps stop the inflammatory process and prevent scarring. 
CLINICAL PRESENTATION
EBA has a wide spectrum of clinical presentations and can affect the skin and mucous membranes. EBA has 5 main phenotypes.
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I) The classical or mechanobullous form is observed in approximately one-third of EBA patients and is characterized by skin fragility in trauma-prone areas, with tense blisters, erosions, atrophic scars, milia formation, anonychia, and digital contracture, especially on the fingers. 88, 92 II) The bullous pemphigoid-like variant presents as vesicles and blisters with erythematous or urticarial lesions, usually without skin fragility or milia formation, mainly in the extremities, trunk, and skin folds.
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III) The cicatricial pemphigoid-like form presents with exclusive or predominant mucous involvement, affecting any stratified squamous cell epithelia, such as ocular, oral, nasal, laryngeal, esophageal, and genital mucosa.
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IV) The Brunsting-Perry pemphigoid-like variant is defined as a vesiculobullous eruption on the head and neck, which may eventually have oral involvement.
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V) The linear IgA bullous dermatosis-like form is characterized by edematous plaques with tense blisters and vesicules that can present in annular or polycyclic arrangement. In this form of EBA, the direct immunofluorescence demonstrates linear IgA deposition in the BMZ. 94 The differential diagnosis of EBA includes bullous systemic lupus erythematosus, porphyria cutanea tarda, and other subepidermal bullous dermatosis, as mentioned in the clinical variants.
DIAGNOSIS
The diagnosis of EBA comprises histopathological analysis and direct (DIF) and indirect (IIF) immunofluorescence, which allow the diagnosis of subepidermal bullous dermatosis. However, they are not always conclusive for the diagnosis of EBA. The definite diagnosis of EBA requires additional techniques that are only available in research centers.
The histopathological evaluation of injured skin in patients with EBA shows subepidermal cleavage, with varying degrees of inflammatory infiltrate. In the mechanobullous form, the inflammatory infiltrate is absent or minimal, whereas in the inflammatory forms of EBA, it is composed of neutrophils with variable numbers of eosinophils, monocytes, and lymphocytes. 
II) General skin care
Local care should be encouraged for better disease control.
Similar to inherited epidermolysis bullosa, the general care includes the prevention of local trauma and infection and the use of non-adherent dressings.
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III) Systemic treatment
A) Introduction
A Cochrane systematic review found 11 non-randomized studies of treatment for EBA, involving interventions in 20 adults and 11 children. 99 Adult patients were treated with various therapeutic modalities, including systemic corticosteroids, immunosuppressants, dapsone, colchicine, and intravenous immunoglobulin.
Most children were treated with systemic corticosteroids and/or dapsone. The authors concluded that there is no recommendation for treating EBA, based on reliable evidence.
B) Medications
Corticosteroids EBA patients, especially those of the mechanobullous form, usually do not experience a good therapeutic response to systemic corticosteroids, such as in other autoimmune blistering diseases.
Despite this limitation, systemic corticosteroids are still considered the first-line treatment for EBA, with usual dosages of 0.5-1.5mg/kg/day; they can be used as monotherapy in some cases of mild disease. 100 A retrospective Spanish study of 12 patients with EBA showed that a dosage greater than 15mg/day is required to control disease activity. 101 However, most patients require adjuvant treatment for better disease control or to avoid undesirable side effects of prolonged use of corticosteroids, such as obesity, hypertension, and osteoporosis. One study demonstrated that the use of methylprednisolone at a high dosage (> 8mg/day) led to earlier remission compared with low-dose use (≤ 8mg/day) and that some patients obtained a good response to pulse therapy with methylprednisolone (500mg for 3 days).
102
Anti-inflammatory agents (dapsone, colchicine, tetracycline)
The main anti-inflammatory benefits of these medications are exerted by an antineutrophilic action. 103 Dapsone use has been described in several cases of EBA. 101, 102, 104 The commonly used dosages range from 25-100mg/ day or 1-2mg/kg/day, with a favorable response being reported in adult and pediatric cases. 105 It should be noted that unlike the condition in adults, EBA in childhood tends to have a better prognosis, usually with a good response to dapsone and systemic corticosteroid. 106, 107 The proposed protocols for the treatment of EBA in the literature include dapsone as one of the first therapeutic options, combined with systemic corticosteroid therapy, primarily for the mild forms of EBA. 100, 101 Common medication side effects include hemolysis and methemoglobinemia. 108 The efficacy of colchicine in EBA was reported for the first time in 1989, with dosages ranging from 0.5-2mg/day. 109 Among adjuvant treatments, colchicine is considered a first-line agent and is frequently associated with systemic corticosteroids. 100 Although it is less common, colchicine has also been reported as a monotherapy, yielding a good clinical response. 110 However, its side effects, especially diarrhea, can limit its use, making it difficult to achieve a sufficient dose to control the disease in certain patients.
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Minocycline is a broad-spectrum tetracycline that inhibits the recruitment of neutrophils and eosinophils as well as cytokine production. 112 A Japanese study that evaluated the clinical and immunological aspects of 105 patients with EBA described minocycline as one of the most common therapeutic options, having been used in 16 patients; however, details regarding the therapeutic response were not specified. 91 A recent case report showed a patient with an inflammatory form of EBA who was treated with various therapeutic options, such as systemic corticosteroid, cyclosporine, and dapsone, responding to the combination of minocycline (200mg/day) and systemic corticosteroid. 112 This study suggested that minocycline may be considered as a therapeutic option in EBA, mainly as an adjuvant in inflammatory forms of the disease.
Immunosuppressants (azathioprine, mycophenolate mofetil, cyclosporine, methotrexate) These medications are commonly used as systemic corticosteroid-sparing agents.
Azathioprine has varying results in the literature. 101, 104, 113 Although its use is well established in pemphigus vulgaris, its application in EBA is less convincing, with other medications, such as dapsone and mycophenolate mofetil, being preferred more often. 114 Mycophenolate mofetil (MMF) is an immunosuppressive agent that alters the proliferation of B and T lymphocytes. 111 In EBA, MMF has been reported to be effective in some refractory cases. 105 A recent study described 4 patients with EBA who were treated with MMF at 2 to 3g/day, with success. 115 One of the limiting factors of its use in daily practice is its high cost.
Cyclosporine is usually used at doses of 4-9mg/kg, leading to disease improvement in recalcitrant cases. 103, 105 A report of 2 patients with the rare association of EBA and acquired hemophilia A demonstrated a good therapeutic response with prednisone and cyclosporine, with no adverse effects. 116 In addition, cyclosporine is considered a relatively safer immunosuppressive drug in pregnancy. 114 Methotrexate is a folic acid analogue and antimetabolite that inhibits the synthesis of DNA and RNA, impairing lymphocyte function. 108 There are no reports of monotherapy in patients with EBA and no data that documents its effectiveness as a systemic cor- 
Extracorporeal photopheresis (ECP)
ECP is an immunomodulatory therapy that was initially used in cutaneous T cell lymphoma that consists on the separation of a peripheral blood leukocyte/lymphocyte-enriched cellular fraction, extracorporeal treatment of 8-MOP/UVA cells, and subsequent reinfusion of cells into the patient. 120 Its main effect in EBA appears to be associated with inhibiting the production of pathogenic autoantibodies by B lymphocytes and producing regulatory T cells. 97 ECP has proven to be efficient in inducing partial to complete remission in patients with recalcitrant EBA and is considered a well-tolerated therapy, with promising results. [121] [122] [123] In the literature, a recent review revealed that 8 patients with severe and refractory EBA were treated with ECP, all of which progressed with clinical improvement. 123 European guidelines on ECP states that such treatment can be used in severe and refractory cases of EBA.
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Rituximab
Rituximab is a chimeric anti-CD20 monoclonal antibody that causes B cell depletion through various mechanisms and is approved for the treatment of B cell lymphoma, rheumatoid arthritis, and granulomatosis with polyangiitis. 125 In the context of autoimmune bullous diseases, its use was initially described for recalcitrant cases of pemphigus and, recently, as first-line treatment in combination with short term prednisone, being effective and potentially safer than a standard regimen of high doses of corticosteroids in patients with moderate to severe pemphigus. 126, 127 Rituximab use in subepidermal bullous diseases, however, is more limited. In EBA, a few promising case reports have been described, usually in patients with recalcitrant disease who have undergone several treatments before rituximab (such as systemic corticosteroid, dapsone, azathioprine, cyclosporine, mycophenolate, and cyclophosphamide), with an effective response. [128] [129] [130] [131] The therapeutic scheme was usually 375mg/m 2 weekly, administered over 4 weeks.
Another proposed scheme is 1g, administered on Days 0 and 14.
Rituximab (375mg/m 2 weekly, managed over 4 weeks), combined with IVIG (2g/kg/monthly cycle), was given to 4 patients who were resistant to conventional therapy, showing an effective and efficient response. 132 In addition, rituximab combined with protein A immunoadsorption has, in some cases, resulted in favorable outcomes. 133, 134 In the authors' personal experience, 5 patients with EBA were treated with rituximab. All patients presented with mechanobullous form, severe mucosal impairment and were resistant to conventional therapy, including systemic corticosteroid therapy (1mg/kg/day), dapsone (100mg/day), cyclosporine (5mg/kg), azathioprine (150mg/day), and mycophenolate mofetil (3g/day). In most cases, rituximab was administered following the rheumatoid arthritis protocol, at 1g IV on Day 0 and 1g IV on Day 14. All patients needed a new drug cycle after 6 months. At present, 2 patients are in complete remission, 1 is in partial remission, and 2 experienced disease relapse after being in complete remission for 1 year.
IV) Classification of EBA severity
There is no standardized severity score for EBA; 2 recent classifications have been proposed in the literature:
Classification I: 103 -Mild EBA: < 5% of body surface affected, without mucosal involvement.
-Moderate EBA: 5% to 15% of body surface affected with at most 2 affected mucous membrane sites, not including ocular involvement.
-Severe EBA: > 5% of body surface affected and > 2 mucous membrane sites involved or ocular involvement.
In mild forms of EBA, use of prednisone (0.5-1mg/kg/day) with additional colchicine and dapsone is suggested. Prednisone In the non-severe localized form, topical corticosteroids are suggested, whereas in the non-severe, more diffuse form, the use of colchicine, dapsone, sulfasalazine, and topical corticosteroid is advised. In severe EBA, cyclosporine or IVIG is recommended; rituximab or ECF can be considered as an alternative. Systemic corticosteroid therapy is reserved for urgent cases, such as laryngeal edema.
The authors of this consensus propose the following classification of EBA severity:
-Non-severe EBA: up to 10% of total body surface involved without functional alteration (flexion contracture of fingers) and absence of severe mucosal involvement (ocular, laryngeal, or esophageal).
-Severe EBA: greater than 10% of total body surface area affected, and/or presence of functional alteration (flexion contracture of fingers), and/or severe mucosal involvement (ocular, laryngeal, or esophageal), or non-severe EBA that is unresponsive to the proposed treatment.
This classification was used for the treatment algorithm below.
V) Proposed treatment algorithm
In the non-severe form of EBA, the first treatment option should be given to stressful situations (such as surgeries and infections), in which the dose of hydrocortisone should be doubled.
In the case of pulse therapy, at the end of 3 days, corticosteroid therapy should be maintained through oral administration of prednisone at 0.5 to 1mg/kg/day.
EVOLUTION AND PROGNOSIS
EBA is a disease that can evolve with high morbidity due to its potential for scarring. The cutaneous involvement in EBA can progress with extensive erosions, atrophic scars, nail dystrophies, and fibrosis, with flexion contracture of fingers, limiting adequate mobility.
Different mucosal sites with stratified squamous epithelium may be affected, such as the conjunctival, upper airway, oral, esophageal, genital, and anal areas.
Ocular involvement in EBA is frequent, with various forms of presentation, including conjunctivitis, symblepharon, keratitis, subepithelial vesiculation, perforation, and corneal opacification. 136, 137 In severe cases, blindness may occur. [136] [137] [138] Upper airway involvement can occur, with formation of synechia, erosions, thickening of the epiglottis, and supraglottic stenosis. 139 Some cases result in acute airway obstruction, requiring a tracheostomy. 139, 140 Esophageal involvement may present as the formation of erosions and stenosis and dysphagia. 113, 141 Sometimes, patients must undergo periodic esophageal dilations and, in extreme cases, gastrostomy.
Mucosal involvement may occur in a silent, chronic manner and progress to life-threatening complications. 142 Such impairments worsen the patients' prognosis, impacting their quality of life and requiring long-term clinical and laboratory follow-up. 104 In this context, multidisciplinary follow-up becomes mandatory for the early diagnosis and detection of subclinical lesions, thus preventing subsequent severe complications. In addition, mucosal involvement may render the disease more difficult to control, requiring aggressive immunosuppressive therapy. Severe EBA
CONCLUSION
